Can I Take Green Tea Extract (EGCG) With Vyleesi (Bremelanotide)?

What Is Vyleesi and How Does It Work?

Bremelanotide (brand name Vyleesi) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women. [1] It binds primarily to MC3R and MC4R in the central nervous system to modulate sexual desire pathways, and patients self-administer a 1.75 mg dose subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. [2]

Pharmacokinetics Relevant to Supplement Interactions

The drug reaches peak plasma concentration (Cmax) in roughly 1 hour after injection. Bremelanotide is metabolized mainly by hydrolysis of the amide bonds rather than by the CYP450 system, although minor CYP3A4 involvement has been noted in the FDA prescribing information. [1] Terminal half-life is approximately 2.7 hours. Because hepatic CYP metabolism is limited, classical drug-supplement CYP interactions are a lower concern than with many oral drugs, but the liver still processes clearance products.

Approved Use and Dosing Limits

The FDA label caps bremelanotide at a maximum of one dose per 24 hours and no more than eight doses per month, a restriction partly intended to limit cumulative cardiovascular and blood pressure exposure. [1] That monthly dose ceiling also means hepatic exposure per month is low compared with a daily oral medication, which is clinically relevant when evaluating additive organ stress.

What Is Green Tea Extract and What Does EGCG Do?

Green tea extract is a concentrated supplement derived from the leaves of Camellia sinensis, standardized in most commercial products to a specific percentage of catechins. Epigallocatechin gallate (EGCG) is the predominant catechin and accounts for much of the extract's biological activity.

Biologically Active Doses vs. Dietary Amounts

A standard cup of brewed green tea contains roughly 50-150 mg of EGCG. [3] Concentrated supplements commonly supply 200-800 mg of EGCG per capsule, which is 4 to 16 times what a single cup delivers. The European Food Safety Authority (EFSA) published a scientific opinion in 2018 concluding that EGCG intakes above 800 mg/day from supplements are associated with signs of liver stress, while dietary intakes below approximately 338 mg/day appear safe in healthy adults. [4]

Hepatotoxicity Signal: How Strong Is the Evidence?

The hepatotoxicity concern is not theoretical. A systematic review of green tea extract adverse events catalogued 34 case reports of liver injury linked to EGCG-containing supplements, with severity ranging from transient transaminase elevation to acute liver failure requiring transplant. [5] The proposed mechanism involves mitochondrial membrane disruption and reactive oxygen species (ROS) generation within hepatocytes, particularly under fasted conditions where EGCG bioavailability increases by roughly 3.5-fold compared with fed conditions. [3]

The U.S. Pharmacopeia (USP) Dietary Supplement Expert Committee concluded in 2008 that products containing more than 700 mg of EGCG per daily serving warrant a cautionary label for liver safety. [5]

How Does Green Tea Extract Interact With Bremelanotide Specifically?

The interaction between EGCG and bremelanotide is primarily pharmacodynamic rather than pharmacokinetic. Both agents can place independent stress on the liver, and when used together, the concern is additive hepatic burden rather than one drug blocking or accelerating the other's metabolism.

Pharmacokinetic Pathway: CYP3A4 and Hydrolysis

Bremelanotide's main clearance route is peptide hydrolysis, not CYP oxidation. [1] EGCG at high concentrations has been reported to inhibit CYP3A4 activity in vitro, with one study showing a roughly 40% reduction in CYP3A4-mediated metabolism at concentrations achievable with high-dose supplementation. [6] Because bremelanotide relies only minimally on CYP3A4, this inhibition is unlikely to produce clinically meaningful plasma-level changes for the drug itself. The pharmacokinetic interaction risk is therefore low.

Pharmacodynamic Pathway: Additive Liver Stress

This is where the real concern lies. Bremelanotide carries a class labeling acknowledgment that liver function has not been studied in patients with significant hepatic impairment. [1] EGCG at supplement doses can independently raise alanine aminotransferase (ALT) and aspartate aminotransferase (AST). A controlled trial by Maki et al. (N=1,075) found that 843 mg/day of EGCG for 12 weeks produced a statistically significant rise in ALT in a subset of participants (P<0.05 vs. Placebo). [7] Even if the absolute ALT rise is modest in an individual, a person whose liver is already managing EGCG-related oxidative stress may have less reserve to handle any additional hepatic demand from a co-administered compound.

Nausea Overlap

Nausea is the most commonly reported adverse event with bremelanotide, occurring in approximately 40% of patients in the key RECONNECT trials (N=1,267 enrolled). [2] High-dose EGCG is also associated with nausea, particularly when taken fasted. [3] Taking both together, especially on an empty stomach, could produce or worsen nausea enough to reduce tolerability and lead to premature discontinuation.

HealthRX Risk Stratification: EGCG + Bremelanotide

| EGCG Daily Dose | Estimated Interaction Risk | Suggested Action | |---|---|---| | Dietary green tea (50-150 mg EGCG) | Negligible | No change needed | | Low-dose supplement (200-400 mg EGCG) | Low to moderate | Disclose to prescriber; take with food | | High-dose supplement (400-800 mg EGCG) | Moderate | Discuss with prescriber; consider dose reduction | | Very high dose (>800 mg EGCG) | Moderate to high | Pause until prescriber clears; baseline LFTs recommended |

What the Clinical Trials Say About HSDD Treatment and Supplement Safety

The two Phase III RECONNECT trials (RECONNECT A and RECONNECT B, combined N=1,267) that supported Vyleesi's FDA approval did not evaluate concurrent supplement use. [2] Participants were generally healthy premenopausal women, and the trials excluded those with significant hepatic disease. This exclusion matters: it means we have no randomized data on how EGCG affects bremelanotide's safety profile, and the absence of data is not the same as evidence of safety.

What FDA Approval Does and Does Not Cover

FDA approval of bremelanotide was based on the RECONNECT trials showing statistically significant increases in satisfying sexual events and decreases in distress scores versus placebo. [2] The FDA label does not address green tea extract specifically, placing the interaction assessment squarely in the prescriber's clinical judgment and the patient's disclosure habits.

Endocrine Society and ISSWSH Guidance

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 clinical practice guideline on HSDD recommends a thorough medication and supplement review before initiating pharmacotherapy, noting that any agent with hepatotoxic potential should be disclosed. [8] The guideline does not name EGCG by name, but the recommendation covers all supplement categories.

Who Is at Highest Risk From This Combination?

Not every woman taking Vyleesi and a green tea supplement will experience a problem. Risk concentrates in specific subgroups.

Pre-existing Liver Conditions

Women with non-alcoholic fatty liver disease (NAFLD), which affects roughly 25% of U.S. Adults according to CDC surveillance data, already have elevated baseline transaminases in a proportion of cases. [9] Adding EGCG-related oxidative stress to a liver with reduced reserve increases the probability that transaminases will cross a clinically meaningful threshold.

Fasted EGCG Use

As noted earlier, EGCG bioavailability increases approximately 3.5-fold when taken in a fasted state. [3] Women who take their EGCG supplement in the morning before eating and then use bremelanotide in the evening face a day where peak EGCG hepatic exposure may still be declining when bremelanotide clearance is beginning. The temporal overlap is not zero.

High-Dose or Multi-Ingredient Fat-Loss Stacks

Many commercial weight-loss supplements combine EGCG with caffeine, synephrine, or other stimulants. A 2017 review of herb-induced liver injury in the U.S. Drug-Induced Liver Injury Network (DILIN) found that multi-ingredient dietary supplements containing green tea extract accounted for a disproportionate share of severe hepatic outcomes compared with single-ingredient products. [10] Women using these stacks face compounded risk.

Alcohol Use

Alcohol is independently hepatotoxic. Concurrent alcohol use, EGCG supplementation, and bremelanotide represents a three-way additive scenario that no trial has evaluated. The FDA label for Vyleesi notes that alcohol can worsen nausea and hypotension; the liver implications of triple co-exposure are extrapolated from general hepatotoxicology principles rather than direct evidence. [1]

Monitoring: What to Watch For and When to Stop

Liver Function Testing

If a woman chooses to continue high-dose EGCG supplementation (above 400 mg/day) while using Vyleesi, the HealthRX medical team recommends a baseline ALT and AST before starting, with a repeat panel at 6-8 weeks. This mirrors the monitoring cadence used in clinical trials studying hepatotoxic supplements. [7]

Symptoms Requiring Immediate Discontinuation

Stop both the supplement and contact a clinician immediately if any of the following appear: jaundice (yellowing of skin or eyes), right upper quadrant abdominal pain, dark urine, or unexplained fatigue combined with nausea. These are early signals of significant hepatocellular injury. The DILIN criteria classify liver injury as clinically significant when ALT exceeds 5 times the upper limit of normal or total bilirubin rises above 2 times normal. [10]

Blood Pressure Monitoring

Bremelanotide transiently increases blood pressure, with mean systolic increases of approximately 6 mmHg lasting 12 hours after injection. [1] Caffeine-containing green tea supplement stacks can also raise blood pressure. Women with borderline hypertension should measure blood pressure in the 2 hours following both a green tea supplement dose and a bremelanotide injection before establishing a routine pattern.

Practical Guidance: What To Do If You Are Already Taking Both

Step 1, Identify Your EGCG Dose

Check the supplement label for the milligrams of EGCG per serving, not just the total green tea extract weight. A product listing "500 mg green tea extract (50% EGCG)" delivers 250 mg of EGCG per capsule. Two capsules daily = 500 mg EGCG, which falls in the moderate-concern range per the framework above.

Step 2, Disclose to Your Prescriber Before Your Next Use of Vyleesi

Do not simply stop the supplement without speaking to a clinician first. Your prescriber needs to know what you are taking to make an informed recommendation. The ISSWSH guideline explicitly positions the prescribing clinician as the coordinator of supplement safety in HSDD management. [8]

Step 3, Time Doses to Minimize Overlap

If your prescriber approves continued low-dose EGCG use, take the supplement with food to reduce fasted-state bioavailability. [3] Use bremelanotide at least 4-6 hours after your last EGCG dose to allow partial clearance. This timing window is practical rather than supported by a dedicated pharmacokinetic study, so treat it as a harm-reduction measure rather than a guarantee.

Step 4, Consider a Lower-Risk Alternative

If you are using green tea extract primarily for weight management or antioxidant effects, dietary green tea (2-3 cups per day providing 100-300 mg EGCG) carries a substantially lower hepatotoxicity signal than concentrated supplements and avoids the dose range associated with liver injury. [4] Discuss alternative strategies with your clinician.

The Pharmacology Behind EGCG's Liver Risk: A Closer Look

Mitochondrial Membrane Disruption

EGCG at high concentrations disrupts the mitochondrial electron transport chain in hepatocytes, reducing membrane potential and triggering cytochrome c release. [5] This pathway is dose-dependent and more pronounced under oxidative stress conditions, such as those caused by alcohol, pre-existing metabolic disease, or concurrent hepatotoxic agents.

Pro-oxidant Behavior at High Doses

Below approximately 100 mg/day, EGCG functions as an antioxidant by scavenging reactive oxygen species. Above several hundred milligrams, particularly in isolated hepatocytes, the catechin can auto-oxidize and act as a pro-oxidant. [3] This dose-dependent polarity is one reason why epidemiological studies of tea drinkers show neutral or beneficial liver effects while clinical trials of high-dose EGCG supplements show transaminase elevations.

UGT1A Enzyme Interactions

EGCG has also been identified as a moderate inhibitor of UDP-glucuronosyltransferase 1A (UGT1A) isoforms in vitro. [6] UGT1A enzymes handle glucuronidation of many compounds including some steroid hormones. For bremelanotide specifically, whose clearance depends mainly on hydrolysis, this is unlikely to be clinically significant. But for women who are also taking hormonal contraceptives or other UGT1A substrates, this inhibitory effect is worth noting separately.

Summary of Evidence Quality

The evidence base for this interaction deserves honest grading.

The hepatotoxicity signal for high-dose EGCG is supported by case series, one controlled clinical trial (Maki et al., N=1,075) [7], a systematic review [5], and a formal EFSA safety assessment [4]. This constitutes moderate-quality evidence.

The pharmacokinetic interaction (CYP3A4 inhibition by EGCG affecting bremelanotide clearance) is supported only by in vitro data [6], which is low-quality evidence for a clinical recommendation.

No randomized controlled trial has directly studied EGCG plus bremelanotide co-administration. The practical guidance in this article is therefore extrapolated from mechanistic data, epidemiological patterns, and expert consensus, and a physician review of your individual case remains the gold standard for a personalized recommendation.